4-Methoxy-7-methylquinoline | 141813-06-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-Methoxy-7-methylquinoline
• CAS: 141813-06-1
• 化学式: C₁₁H₁₁NO
• mdl: MFCD09261116
• 分子量: 173.214
• InChiKey: GLUHCNQUUKDDIG-UHFFFAOYSA-N

物化性质

• 沸点：
  266.7±20.0 °C(Predicted)
• 密度：
  1.102±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-Benzoyl-3-bromo-4-methoxy-7-methyl-1,2,3,4-tetrahydro-quinoline-2-carbonitrile 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以46.3%的产率得到4-Methoxy-7-methylquinoline
  参考文献：
  名称：

  Synthesis of 4-Alkoxyquinolines from Quinoline Reissert Compounds

  摘要：

  The quinoline Reissert compound (5a) was converted to 1-benzoyl-3-bromo-2-cyano-1, 2, 3, 4-tetrahydro-4-methoxyquinoline (6a) by successive treatment in methanol with bromine and aq. sodium carbonate. Hydrolysis of 6a with hydrochrolic acid gave 3-bromoquinoline (4; R = H), but that with aq. sodium hydroxide afforded 4-methoxyquinoline (7a). Reissert compounds derived from some quinoline derivatives (5) gave the corresponding 4-methoxyquinolines (7) through tetrahydroquinolines (6) in a similar way.

  DOI：

  10.3987/com-91-5945

文献信息

• [EN] AKT3 MODULATORS<br/>[FR] MODULATEURS DE AKT3
  申请人：GEORGIAMUNE LLC

  公开号：WO2021226458A1

  公开（公告）日：2021-11-11

  Compounds of Formula la, lb, or Ic, (Ia); (Ib); or (Ic), are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 in vitro or in vivo, and can also be used, individually or in combination with other agents, in the prevention or treatment of a variety of conditions. Methods for synthesizing the compounds are described. Pharmaceutical compositions and methods of using these compounds or compositions, individually or in combination with other agents or compositions, in the prevention or treatment of a variety of conditions are also described.

  本文描述了化合物la、lb或Ic的公式(Ia)；(Ib)；或(Ic)，其中各种取代基在此处定义。这些化合物可以在体外或体内调节Akt3的性质或效果，并且还可以单独或与其他药剂结合在预防或治疗各种疾病方面使用。描述了合成这些化合物的方法。还描述了药物组合物和使用这些化合物或组合物的方法，单独或与其他药剂或组合物结合在预防或治疗各种疾病方面。
• Heteroaryl Substituted Quinolin-4-Ylamine Analogues
  申请人：Caldwell M. Timothy

  公开号：US20080085901A1

  公开（公告）日：2008-04-10

  Heteroaryl substituted quinolin-4-ylamine analogues of Formula I are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了公式I的杂环取代的喹啉-4-胺类似物。这些化合物是配体，可用于体内或体外调节特定受体活性，并且在治疗与人类、家养伴侣动物和家畜动物的病理性受体激活相关的疾病方面特别有用。提供了用于治疗此类疾病的制药组合物和方法，以及用于受体定位研究的配体使用方法。
• SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES
  申请人：Bakthavatchalam Rajagopal

  公开号：US20090286767A1

  公开（公告）日：2009-11-19

  Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了替代的喹啉-4-胺类似物。这些化合物是配体，可以用于体内或体外调节特定受体的活性，并且在治疗与人类、家养伴侣动物和家畜动物的病理性受体激活相关的情况方面特别有用。提供了制药组合物和使用它们治疗这些疾病的方法，以及使用这样的配体进行受体定位研究的方法。
• TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD

  公开号：EP3293177A1

  公开（公告）日：2018-03-14

  The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II):

  本发明涉及一种酪氨酸激酶抑制剂及其药物组合物。本发明的酪氨酸激酶抑制剂具有下式（I）或（II）所示的结构：
• US7488740B2
  申请人：——

  公开号：US7488740B2

  公开（公告）日：2009-02-10